China & HK Strategy: 1H25 Preview - Where Are the Upside and Downside Surprises?
The companies under our coverage are expected to report 16.8% earnings growth for 1H25, with 2Q25 accelerating to 30.8%. Top performers include...
Fosun (656 HK): ClubMed Spin-Off Won't Move The Needle
At 0.38x P/B, Fosun is not expensive. The five-year average P/B is 0.3x. Spinning off the ClubMed unit won't narrow the discount to book. I might...
Smartkarma Originals